Forecast

The analysts' average price target is €9.53 (+125.30%). The median is €9.53 (+125.30%).

Buy	10
Hold	0
Sell	0

News Go to news feed

Aquestive focuses on market launch of Anaphylm and plans resubmission to the FDA

At the H.C. Wainwright conference, Aquestive highlighted Anaphylm as a new treatment option for severe allergies and announced it will resubmit the approval application to the FDA later this month. The company emphasizes rapid absorption (therapeutic blood levels in ~5 minutes), revised packaging and a targeted launch model with 75 field sales representatives aiming to reach 8,000 healthcare professionals. Source data point to a US market potential of up to ~$2 billion and peak global sales for Anaphylm of around $1 billion, with management saying funding (RTW, Oaktree) extends well into 2028. Key hurdles remain FDA approval, reimbursement by insurers and getting physicians and patients to switch from autoinjectors to the new product. » More on de.investing.com
Aquestive Therapeutics to resubmit Anaphylm NDA after packaging fixes, readies allergist-focused launch

Aquestive Therapeutics will resubmit the Anaphylm NDA before the end of Q3 after revised packaging, labeling and instructions significantly reduced pouch-opening, film-tearing and administration errors in validation studies. Management assumes a six-month FDA review but says the agency could designate a two-month review; regulatory filings in Canada, Europe and the U.K. are planned starting in Q4. Q2 revenue rose 38% to $13.8 million and adjusted EBITDA loss narrowed to $5.2 million, while reported net loss widened to $22.9 million due mainly to an $11.7 million debt-extinguishment charge; the company reiterated 2026 revenue guidance of $46–50 million. Aquestive ended June with $98.5 million cash, completed a $150 million facility with Oaktree, and expects potential post-approval funding of $75 million from RTW and $20 million from Oaktree. » More on finance.yahoo.com
Aquestive Therapeutics surpasses Q2 revenue expectations, EPS weighed down by debt repayment

Aquestive reported Q2 revenue of $13.82 million, beating analysts’ estimates, while reported EPS of -$0.18 missed expectations, mainly due to a one-time $11.7 million charge from debt repayment. Adjusted EBITDA improved markedly and operating business grew; the company holds $98.5 million in cash. Aquestive reaffirmed its full-year guidance (revenue $46–50 million, adjusted non-GAAP EBITDA loss $30–35 million) and plans to refile the NDA for Anaphylm with the FDA before the end of Q3. The next catalyst is the FDA review of Anaphylm; risks remain timing, commercial uptake and continued losses. » More on de.investing.com

Financials

In the last quarter, AQUESTIVE THERAP. DL-,001 had revenue of €12.11m and net profit of -€20.03m

(EUR)	June 2026	YoY
Revenue	12.11m	42.67%
Gross profit	8.59m	86.02%
Net profit	-20.03m	74.29%
EBITDA	-16.45m	112.33%

Fundamentals

Metric	Value
Market capitalization	€519.81m
Number of shares	125.47m
52-week high/low	€6.54 - €2.54
Dividends	No
Beta	1.47
P/E ratio	-7.35
PEG ratio	-6.55
P/B ratio	-10.56
P/S ratio	11.09

Company profile

Aquestive Therapeutics, Inc. ist ein pharmazeutisches Unternehmen, das sich auf die Identifizierung, Entwicklung und Vermarktung verschiedener Produkte konzentriert, um ungedeckten medizinischen Bedarf in den Vereinigten Staaten und international zu decken. Das Unternehmen vermarktet Sympazan, eine orale lösliche Filmformulierung von Clobazam zur Behandlung des Lennox-Gastaut-Syndroms; Suboxone, eine sublinguale Filmformulierung von Buprenorphin und Naloxon zur Behandlung von Opioidabhängigkeit; Zuplenz, eine orale lösliche Filmformulierung von Ondansetron zur Behandlung von Übelkeit und Erbrechen im Zusammenhang mit Chemotherapie und postoperativer Genesung; und Azstarys, ein einmal täglich einzunehmendes Produkt zur Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung. Die firmeneigenen Produktkandidaten umfassen Libervant, eine bukkale lösliche Filmformulierung von Diazepam zur Behandlung von Krampfanfällen, und Exservan, eine orale lösliche Filmformulierung von Riluzol zur Behandlung der amyotrophen Lateralsklerose. Die firmeneigene Pipeline komplexer Molekülprodukte umfasst AQST-108, eine sublinguale Filmformulierung, die systemisches Epinephrin für die Behandlung anderer Erkrankungen als Anaphylaxie liefert; AQST-305, eine sublinguale Filmformulierung von Octreotid für die Behandlung von Akromegalie; und AQST-109, ein oral verabreichter Epinephrin-Produktkandidat für die Notfallbehandlung von allergischen Reaktionen, einschließlich Anaphylaxie. Darüber hinaus entwickelt das Unternehmen KYNMOBI, eine sublinguale Filmformulierung von Apomorphin zur Behandlung von episodischen Auszeiten bei der Parkinson-Krankheit. Aquestive Therapeutics, Inc. wurde im Jahr 2004 gegründet und hat seinen Hauptsitz in Warren, New Jersey.